🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)

    Fondazione Telethon ETS

    Ovarian cancer

    phase 2 other active

    1 trial

  2. AB-101

    Artiva Biotherapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  3. AB-201

    Artiva Biotherapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  4. AB-729

    Arbutus Biopharma Corp

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  5. AB680

    Arcus Biosciences

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  6. AB8939, Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets

    AB Science

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  7. ABBV-066, Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  8. ABBV-066, Lutikizumab, ABBV-382, ABBV-066 / Risankizumab, ABBV-8736

    AbbVie Deutschland GmbH & Co. KG

    Moderate to Severe Crohn’s Disease

    phase 2 small molecule active

    1 trial

  9. ABBV-154

    AbbVie

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  10. ABBV-552

    AbbVie

    Alzheimer's Disease (AD)

    phase 2 small molecule completed

    1 trial

  11. ABC294640

    Apogee Therapeutics

    Carcinoma, Hepatocellular

    phase 2 small molecule terminated

    1 trial

  12. ABC294640

    Apogee Therapeutics

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule terminated

    1 trial

  13. ABC294640

    RedHill Biopharma

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  14. ABEMACICLIB , RO7197597

    Fondazione Telethon ETS

    ER-positive, HER2-negative Early breast cancer

    phase 2 small molecule active

    1 trial

  15. ABI-H0731

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 2 small molecule terminated

    6 trials

  16. ABIRATERONE, DAROLUTAMIDE, DZR123, -, -, ABIRATERONE, DZR123, DAROLUTAMIDE

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  17. ABO-102

    ABEONA THERAPEUTICS INC.

    MPS IIIA

    phase 2 small molecule terminated

    1 trial

  18. ABO-102, ABO-102, ABO-102

    Lacuna Pharma Pty Ltd

    Mucopolysaccharidosis type IIIA

    phase 2 small molecule active

    1 trial

  19. ABP-450

    AEON Biopharma

    Migraine

    phase 2 small molecule terminated

    2 trials

  20. ABP-450

    AEON Biopharma

    Cervical Dystonia

    phase 2 small molecule completed

    2 trials

  21. ABTL0812, IRINOTECAN, TEMOZOLOMIDE

    The George Institute

    Relapsed/refractory neuroblastoma and other solid tumours

    phase 2 small molecule active

    1 trial

  22. ACETYLCYSTEINE , DEXAMETHASONE , DIPHENHYDRAMINE , GLUCOSE

    Inhibrx Biosciences

    Unresectable or metastatic conventional chondrosarcoma

    phase 2 small molecule active

    1 trial

  23. ADALIMUMAB, USTEKINUMAB , ADALIMUMAB , USTEKINUMAB, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    Folliculitis decalvans

    phase 2 small molecule active

    1 trial

  24. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources